---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-013235"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T04:58:47.211473+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex licenses NYU patent for Reqorsa gene therapy in mesothelioma; TUSC2 down in 84%

## Summary
- Exclusive patent license with NYU Langone Health for Reqorsa (quaratusugene ozeplasmid) to treat mesothelioma.
- TUSC2 tumor suppressor gene is downregulated in 84% of mesotheliomas; Reqorsa delivers TUSC2.
- Preclinical data showed decreased cell proliferation/invasion and increased apoptosis in all four MPM cell lines.
- Genprex formed a Mesothelioma Clinical Advisory Board of four leading researchers to guide the program.
- About 3,000 new US cases/yr; life expectancy 18 months, 3-year survival rate 23% with treatment.

## SEC filing metadata
- accession: 0001437749-25-013235
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925013235/0001437749-25-013235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925013235/gnpx20250424_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-013235
- JSON: https://secwatch.observer/filing/0001437749-25-013235.json
- Plain text: https://secwatch.observer/filing/0001437749-25-013235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.